SPBK 1 SR-BK ASA NK 25/ NO0010631567 /
30.05.2024 08:12:32 | Diff. -0,200 | Volumen | Geld08:12:36 | Brief08:12:36 | Tageshoch | Tagestief |
---|---|---|---|---|---|---|
11,540EUR | -1,70% | 0 Umsatz: 0.000 |
11,540Geld Vol: 130 | 11,900Brief Vol: 130 | 11,540 | 11,540 |
GlobeNewswire
08:35
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
GlobeNewswire
08:30
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimi...
GlobeNewswire
08:30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
08:30
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
GlobeNewswire
08:30
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Erste Seite
- Zurück
- 1
- 2
- 3
- 4
- Weiter
- Letzte Seite